AstraZeneca: Liver Neoplasms trials
The registry lists 10 Liver Neoplasms studies with AstraZeneca as lead sponsor. 1 are open to participants now and 1 have results posted.
Phase 1 4Phase 2 3Phase 3 4No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.CompletedNCT01498952Phase 1Results posted
- A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular CarcinomaActive, not recruitingNCT06084884Phase 1/2
- A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive, not recruitingNCT06040099Phase 2
- Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT05883644Phase 3
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
- Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative TreatmentCompletedNCT03847428Phase 3
- A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive, not recruitingNCT03778957Phase 3
- Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid TumoursCompletedNCT00475956Phase 1